VNRX Volitionrx Ltd

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: VNRX

Price (delayed)

$0.8909

Market cap

$73.11M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.5

Enterprise value

$58.24M

Volition is a multi-national epigenetics company developing simple, easy to use, costeffective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to ...

Highlights
The revenue has surged by 153% year-on-year and by 19% since the previous quarter
The gross profit has soared by 153% YoY and by 19% QoQ
VNRX's debt is up by 36% QoQ and by 18% YoY
Volitionrx's net income has decreased by 17% YoY and by 4.3% from the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.volitionrx.com
Peers: ONVO

Key stats

What are the main financial stats of VNRX
Market
Shares outstanding
82.07M
Market cap
$73.11M
Enterprise value
$58.24M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
81.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
75.12
Earnings
Revenue
$775,302
EBIT
-$35.1M
EBITDA
-$33.68M
Free cash flow
-$19.15M
Per share
EPS
-$0.5
Free cash flow per share
-$0.27
Book value per share
-$0.1
Revenue per share
$0.01
TBVPS
$0.39
Balance sheet
Total assets
$27.95M
Total liabilities
$36.66M
Debt
$5.86M
Equity
-$7.8M
Working capital
-$9.98M
Liquidity
Debt to equity
-0.75
Current ratio
0.69
Quick ratio
0.66
Net debt/EBITDA
0.44
Margins
EBITDA margin
-4,344.7%
Gross margin
100%
Net margin
-4,555.5%
Operating margin
-4,641.8%
Efficiency
Return on assets
-154.2%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-4,526.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VNRX stock price

How has the Volitionrx stock price performed over time
Intraday
1.24%
1 week
-2.1%
1 month
18.31%
1 year
-55.01%
YTD
24.25%
QTD
17.69%

Financial performance

How have Volitionrx's revenue and profit performed over time
Revenue
$775,302
Gross profit
$775,302
Operating income
-$35.99M
Net income
-$35.32M
Gross margin
100%
Net margin
-4,555.5%
The revenue has surged by 153% year-on-year and by 19% since the previous quarter
The gross profit has soared by 153% YoY and by 19% QoQ
The company's operating margin has surged by 55% YoY and by 14% QoQ
VNRX's net margin has soared by 54% YoY and by 12% QoQ

Growth

What is Volitionrx's growth rate over time

Valuation

What is Volitionrx stock price valuation
P/E
N/A
P/B
N/A
P/S
81.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
75.12
The company's EPS rose by 9% YoY and by 6% QoQ
The revenue has surged by 153% year-on-year and by 19% since the previous quarter
The stock's P/S is 98% below its 5-year quarterly average of 5025.1 and 51% below its last 4 quarters average of 166.0

Efficiency

How efficient is Volitionrx business performance
The company's return on sales has surged by 54% YoY and by 12% QoQ
Volitionrx's ROA has decreased by 24% YoY but it has increased by 7% from the previous quarter

Dividends

What is VNRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VNRX.

Financial health

How did Volitionrx financials performed over time
The company's total assets is 24% lower than its total liabilities
The company's total liabilities has surged by 75% QoQ and by 71% YoY
The company's total assets has surged by 55% QoQ and by 53% YoY
VNRX's debt is 175% higher than its equity
The company's debt to equity has surged by 64% QoQ and by 61% YoY
VNRX's debt is up by 36% QoQ and by 18% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.